A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients.

Trial Profile

A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs AZD 1981 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SWEAPEA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 17 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top